AgroFresh Expands Global Post-Harvest Solutions Portfolio with NatuWrap® in Exclusive Distribution Agreement with Nabaco®
PHILADELPHIA and SAN MARCOS, Texas, June 18, 2025 /CNW/ -- AgroFresh Solutions, Inc., a global leader in post-harvest quality and freshness solutions, and Nabaco ®, Inc., a platform science company specializing in eco-friendly solutions for farmers, produce packers, and beyond, including its NatuWrap ® fruit protection technologies, today announced an exclusive distribution agreement. AgroFresh will serve as the global commercial partner for NatuWrap, bringing the solution to fresh produce packers and processors worldwide. The agreement adds to AgroFresh's growing portfolio of innovative freshness technologies that meet the produce industry's desire for more natural solutions.
"At AgroFresh, we're focused on delivering impactful solutions that address the evolving needs of our customers," said AgroFresh Chief Executive Officer (CEO) Clint Lewis. "Our company aim is to continuously identify unique, novel technologies, developed internally or through our partners, that address the needs of our customers. NatuWrap, developed by Nabaco, Inc., is a tangible example of this innovation commitment, helping to sustainably protect fruit quality throughout the produce supply chain."
NatuWrap is a food - grade solution made from USDA National Organic Program (NOP) listed ingredients and is Organic Materials Review Institute (OMRI) certified. It forms a gentle, protective barrier that helps reduce scuffing, bruising and other damage during handling and storage. This delivers meaningful quality benefits across a variety of crops, including apples, pears, citrus, and cherries. As the U.S. cherry packing season begins, NatuWrap has been shown to reduce pitting and help maintain greener, fresher-looking stems, resulting in higher-quality fruit at retail.
"NatuWrap represents a new standard in fruit protection – novel, effective and easy to integrate into existing operations," said Nabaco CEO Jamie Strachan. "AgroFresh's strong global reach and deep experience in post-harvest solutions makes them the ideal partner to scale the benefits of our technology to the widest possible range of fruit and vegetable packers and processors."
This agreement is the latest in a series of strategic partnerships and new innovations from AgroFresh, underscoring the company's commitment to transforming the fresh produce industry with smart, sustainable post-harvest technologies.
About AgroFresh
AgroFresh is the global leader in post-harvest quality and freshness solutions that enhance quality and extend shelf-life of fresh produce, reducing food loss and waste. AgroFresh has been innovating for more than 40 years to address fresh produce supply chain challenges from all angles with a full suite of integrated storage, packing line and digital solutions. As the pioneer of SmartFresh ™, the world's first introduction to 1-MCP technology used to slow ripening, and Uvasys ™, the world's first laminated SO 2 generating sheets that prevent fungal decay in produce, AgroFresh empowers growers, packers and retailers to succeed in delivering fresh, quality and sustainable produce from harvest to home. To learn more about AgroFresh, visit www.agrofresh.com.
About Nabaco
Nabaco, Inc. is a Texas-based materials science company revolutionizing industries with its patented, eco-friendly solutions for farmers, produce packers, and beyond. Our flagship post-harvest product, NatuWrap ®, is a food-grade, temporary barrier designed to protect fruits and vegetables during processing and storage. By helping packers improve quality and yield, NatuWrap ® supports better returns to the farm and the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Arizona Metals Announces Adjournment of Annual and Special Meeting
/ NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/ TORONTO, June 18, 2025 /CNW/ - Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) (the "Company" or "Arizona Metals") announces that its Annual and Special Meeting (the "Meeting") of shareholders ("Shareholders") of the Company, was convened as scheduled on June 18, 2025, and adjourned until June 26, 2025, at 11:00 a.m. (Toronto time) at the same virtual venue. The next proxy voting cut-off deadline will be 11:00 a.m. (Toronto time) on Tuesday, June 24, 2025. Details to access the Meeting for those Shareholders who wish to attend and participate at the Meeting remain the same and are reproduced below. The Chair adjourned the Meeting in an effort to encourage greater Shareholder participation at the Meeting. By the original proxy cutoff time the Company had received proxies from shareholders representing less than half of its outstanding shares, and a number of Shareholders have contacted the Company citing delays in meeting the voting cut-off deadline for the Meeting or issues with voting of their shares online. The board of directors of the Company has decided that it is in the best interest of the Company and its Shareholders to postpone the Meeting to allow for a broader level of participation by Shareholders to ensure good corporate governance. YOUR VOTE CONTINUES TO BE IMPORTANT – IF YOU HAVE NOT DONE SO, PLEASE VOTE TODAY The proxy voting deadline is 11:00 p.m. (Toronto time) on Tuesday, June 24, 2025. Meeting Details Shareholders of record as of May 20, 2025, will continue to have the right to vote at the Meeting. The Company encourages all shareholders to vote their shares in advance of the Meeting, in accordance with the instructions provided in the previously distributed proxy materials. Any shareholders who previously voted online or by phone or submitted proxies that were accepted by the Chair of the Meeting do not need to take any further action (unless they wish to change their vote) as those proxies remain valid for use at the Meeting on June 26, 2025. The Meeting will be held on Thursday, June 26, 2025 at 11:00 a.m. (Toronto time) and will continue to be held in a virtual only format which will be conducted via live audio webcast available online using at At this website, shareholders will be able to participate in the Meeting, submit questions and vote their shares while the Meeting is being held. For complete details and access to all relevant documents related to the Meeting, please visit or the Company's profile on SEDAR+ at HOW TO VOTE Shareholders are encouraged to vote in advance of the meeting via the internet or telephone using the control number found on the form of proxy or voting instruction form previously mailed by the Company. To ensure that their vote is counted, shareholders are encouraged to vote well in advance of the proxy voting deadline on Tuesday, June 24, 2025 at 11:00 a.m. (Toronto time). About Arizona Metals Corp Arizona Metals Corp owns 100% of the Kay Project in Yavapai County, which is located on 1669 acres of patented and BLM mining claims and 193 acres of private land that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a "proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 g/t gold, 3.03% zinc, and 55 g/t silver." The historic estimate at the Kay Mine Project was reported by Exxon Minerals in 1982. (Fellows, M.L., 1982, Kay Mine massive sulphide deposit: Internal report prepared for Exxon Minerals Company) The Kay Project's historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a Qualified Person before the historic estimate can be verified and upgraded to be a current mineral resource. A Qualified Person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource. The Kay Project is a steeply dipping VMS deposit that has been defined from a depth of 60 m to at least 900 m. It is open for expansion on strike and at depth. The Company also owns 100% of the Sugarloaf Peak Project, in La Paz County, which is located on 4,400 acres of BLM claims. The Sugarloaf Peak Project is a heap-leach, open-pit target and has a historic estimate of "100 million tons containing 1.5 million ounces gold" at a grade of 0.5 g/t (Dausinger, N.E., 1983, Phase 1 Drill Program and Evaluation of Gold-Silver Potential, Sugarloaf Peak Project, Quartzsite, Arizona: Report for Westworld Inc.) The historic estimate at the Sugarloaf Peak Project was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a Qualified Person before the historic estimate can be verified and upgraded to a current mineral resource. A Qualified Person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource. Qualified Person and Quality Assurance/Quality Control The qualified person who reviewed and approved the technical disclosure in this news release is David Smith, CPG, VP of Exploration of the Company and a qualified person as defined in National Instrument43-101 – Standards of Disclosure for Mineral Projects. Disclaimer This press release contains statements that constitute "forward-looking information" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements contained in this press release include, without limitation, statements regarding the holding of the timing of the adjourned Meeting. In making the forward- looking statements contained in this press release, the Company has made certain assumptions. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward- looking statements or otherwise. SOURCE Arizona Metals Corp.
Cision Canada
2 hours ago
- Cision Canada
Signicast Acquires FS Precision, Adding Titanium Casting Capabilities to Expand Aerospace and Defense Offerings
HUTCHINS, Texas, June 18, 2025 /CNW/ -- Signicast, a Form Technologies company and a leading provider of precision investment casting solutions, is proud to announce the acquisition of FS Precision, a strategic move that adds titanium casting to its portfolio and further strengthens its position in the aerospace and defense industries. The acquisition includes FS Precision's intellectual property and specialized equipment, which Signicast has since upgraded, enabling the company to meet growing demand for titanium and other high-performance alloys across critical applications. The integration of FS Precision's technology enhances Signicast's ability to deliver fully integrated solutions-from inception to final assembly-while providing expanded capabilities in vacuum alloy manufacturing, advanced machining, sub-assembly, and packaging, ensuring comprehensive production solutions under one roof. Expanding Expertise in Aerospace and Defense With AS9100, NADCAP, and SOPHIA certifications, Signicast has established itself as a clear expert in the aerospace and defense sectors. The acquisition of FS Precision allows the company to take a significant step into the world of vacuum alloy manufacturing, particularly with titanium-a critical material for aerospace and defense applications. With this acquisition, Signicast is now able to offer titanium casting as part of its portfolio, further reinforcing its commitment to delivering high-performance components for these demanding industries. Growing Capacity and Capabilities Production has already commenced at Signicast's Hutchins, TX facility, leveraging the new capabilities acquired from FS Precision. This facility will serve as the cornerstone for growth in the vacuum alloy and titanium manufacturing markets. Signicast is also planning to further expand its capacity to meet growing demand from the aerospace, defense, and other advanced manufacturing markets. Strategic Vision for the Future "The acquisition of FS Precision represents a major milestone for Signicast," said Marc Riquelme, President of Signicast, "By combining FS Precision's expertise with our own advanced manufacturing capabilities, we are uniquely positioned to serve the aerospace and defense markets with innovative, high-quality solutions. This acquisition reflects our commitment to meeting the evolving needs of our customers and driving growth across key industries." Signicast's expanded portfolio now includes capabilities in titanium and vacuum alloy manufacturing, ensuring the delivery of durable, lightweight, and high-performing components essential for critical applications. About Signicast Signicast, a division of the Form Technologies group of precision metal manufacturers, is a global leader in precision investment casting, delivering fully integrated manufacturing solutions for a variety of industries, including aerospace, defense, medical, and automotive. With advanced facilities and a commitment to innovation, Signicast provides unmatched quality and expertise from design to final assembly.
Cision Canada
3 hours ago
- Cision Canada
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /CNW/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs, and their lack of life-extension successes. That said, with the recent close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers remain optimistic. For investors to note, oncology innovators have provided recent developments to pay attention to, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Galectin Therapeutics, Inc. (NASDAQ: GALT), ProPhase Labs, Inc. (NASDAQ: PRPH), CG Oncology, Inc. (NASDAQ: CGON), and Perspective Therapeutics, Inc. (NYSE-American: CATX). With reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. According to analysts at ResearchAndMarkets, the global oncology market is projected to reach US$866.1 billion by 2034, rising at a 10.8% CAGR, while Vision Research Reports projects the global oncology market to surpass US$903.81 billion by 2034, at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) just announced a major leadership transition that could mark a pivotal chapter in its clinical and corporate trajectory. The company has appointed Jared Kelly as Chief Executive Officer and member of the Board, a move that brings in a seasoned biotech dealmaker known for high-value M&A and immuno-oncology strategy. Kelly most recently played a central role (as General Counsel) in the $2 billion sale of Ambrx Biopharma to Johnson & Johnson. Prior to that, he advised numerous biotech firms on licensing and acquisitions during his tenure at leading law firms Kirkland & Ellis LLP and Lowenstein Sandler LLP. In joining Oncolytics, he inherits one of the most intriguing immunotherapy agents and pipelines in clinical oncology: pelareorep, a virus-based agent with broad synergy potential in solid and hematologic tumors. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear priority: advancing pelareorep toward late-stage inflection points with a capital-efficient and partnership-aware strategy. The asset currently holds FDA Fast Track designation in both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare distinction that reinforces its regulatory momentum. In trials to date, pelareorep has consistently demonstrated immune activation, synergy with chemotherapies and checkpoint inhibitors, and unusually strong response rates across difficult-to-treat cancers. In metastatic pancreatic cancer (mPDAC), pelareorep has delivered over 60% objective response rates in tumor evaluable patients across Phase 1 and 2 studies—more than double those observed in historical controls — and, separately, two-year survival rates 4-6 times those observed in control patients or in prior studies. In HR+/HER2- metastatic breast cancer, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed meaningful survival benefit. And in anal cancer, early data from a phase 2 cohort combining pelareorep with a checkpoint inhibitor showed partial or complete responses in nearly half of evaluable patients—far exceeding historical norms for monotherapy. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." To align incentives with long-term shareholder value, Kelly's compensation package includes equity and milestone-based awards tied to future strategic transactions and financings. The structure reflects Oncolytics' intention to drive both clinical and corporate progress without overextending its cap table—while remaining attractive to potential collaborators. As multiple programs advance within the GOBLET study—including pancreatic and anal cancer cohorts backed by regulatory support and third-party funding— Oncolytics appears poised to benefit from a combination of scientific traction, capital flexibility, and strategic leadership. Photo - In other recent industry developments and happenings in the market include: Galectin Therapeutics, Inc. (NASDAQ: GALT) is advancing belapectin, a galectin-3 inhibitor with applications in both MASH cirrhosis and oncology, including combination immunotherapy for head and neck cancers. The company recently presented updated data at the 2025 EASL Congress highlighting statistically significant improvements in liver stiffness and reduced varices progression. "This quarter, we remained laser-focused on advancing additional analyses for belapectin," said Joel Lewis, CEO and President of Galectin Therapeutics. "We look forward to sharing more biomarker data as it becomes available." With Fast Track Designation in place, Galectin continues to evaluate expansion into cancer indications pending a development partner. ProPhase Labs, Inc. (NASDAQ: PRPH) has recently reported successful validation of its BE-Smart™ molecular test in detecting esophageal cancer using brush cytology samples, showing a technical success rate above 95%. "The ability to run BE-Smart on brush biopsy samples opens the door to much broader clinical use," said Ted Karkus, CEO of ProPhase Labs. "BE-Smart now stands apart as the only advanced molecular test designed to work with both forceps biopsies and brush-based tissue collection." The company is positioning BE-Smart for near-term commercialization, targeting the $10 billion esophageal disease testing market. With dual compatibility across standard biopsy methods, BE-Smart is designed to improve early detection and risk stratification for deadly cancers like EAC. CG Oncology, Inc. (NASDAQ: CGON) continues to progress its lead candidate cretostimogene, an oncolytic immunotherapy aimed at non-muscle invasive bladder cancer (NMIBC). "With best-in-disease durability and tolerability data from the BOND-003 Cohort C registrational trial recently presented at AUA, we are well positioned to initiate our BLA submission in the second half of the year for the treatment of patients with HR NMIBC unresponsive to BCG," said Arthur Kuan, Chairman and CEO of CG Oncology. "If approved, I'm confident that cretostimogene is well positioned to become backbone therapy in NMIBC, potentially addressing more than 70% of the market opportunity in need of a new and innovative therapy." At the 2025 AUA Annual Meeting, the company reported a 42.3% complete response at 24 months in its BOND-003 Cohort C, with nearly all patients avoiding progression to invasive disease. CG plans to initiate its BLA submission in the second half of 2025 while advancing multiple cohorts across BCG-unresponsive and intermediate-risk populations. Backed by over $688 million in cash and marketable securities, CG Oncology is positioned to reach multiple late-stage milestones over the next 12 months. Perspective Therapeutics, Inc. (NYSE-American: CATX) announced updated Phase 1/2a trial results for [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting, with promising signs of durability and safety in patients with progressive SSTR2-positive neuroendocrine tumors. "[212Pb]VMT-α-NET is emerging as an exciting potential treatment option for patients with progressive NETs, with continued durability of anti-tumor activity at the dose level used in Cohort 2 and a favorable tolerability profile seen so far," said Vikas Prasad, MD, Associate Professor of Radiology at the Mallinckrodt Institute of Radiology, Siteman Cancer Center. "I am eager to find more treatments to help my patients fight hard against their disease and return to their normal lives." Among nine early patients in Cohorts 1 and 2, seven remained progression-free after a year, with multiple confirmed objective responses now observed. Safety data from 42 total treated patients showed no dose-limiting toxicities, no Grade 4/5 adverse events, and no treatment-related discontinuations. The company is now in discussions with the FDA to finalize dose selection and continue advancement of this alpha-emitting radiotherapeutic platform. CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
